Viewing Study NCT07176650


Ignite Creation Date: 2025-12-24 @ 5:25 PM
Ignite Modification Date: 2025-12-29 @ 2:19 AM
Study NCT ID: NCT07176650
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-09-16
First Post: 2025-09-01
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Sponsor: Shanghai Henlius Biotech
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module